These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 21251813)

  • 61. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.
    Partridge AH; Rumble RB; Carey LA; Come SE; Davidson NE; Di Leo A; Gralow J; Hortobagyi GN; Moy B; Yee D; Brundage SB; Danso MA; Wilcox M; Smith IE
    J Clin Oncol; 2014 Oct; 32(29):3307-29. PubMed ID: 25185096
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Presentation and management of docetaxel-related adverse effects in patients with breast cancer.
    Ho MY; Mackey JR
    Cancer Manag Res; 2014; 6():253-9. PubMed ID: 24904223
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells.
    Sprowl JA; Reed K; Armstrong SR; Lanner C; Guo B; Kalatskaya I; Stein L; Hembruff SL; Tam A; Parissenti AM
    Breast Cancer Res; 2012 Jan; 14(1):R2. PubMed ID: 22225778
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer.
    Moulder S; Gladish G; Ensor J; Gonzalez-Angulo AM; Cristofanilli M; Murray JL; Booser D; Giordano SH; Brewster A; Moore J; Rivera E; Hortobagyi GN; Tran HT
    Cancer; 2012 May; 118(9):2378-84. PubMed ID: 22006179
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer.
    Walker LG; Eremin JM; Aloysius MM; Vassanasiri W; Walker MB; El-Sheemy M; Cowley G; Beer J; Samphao S; Wiseman J; Jibril JA; Valerio D; Clarke DJ; Kamal M; Thorpe GW; Baria K; Eremin O
    BMC Cancer; 2011 May; 11():179. PubMed ID: 21592370
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
    Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P
    J Clin Oncol; 2009 Aug; 27(22):3611-9. PubMed ID: 19470941
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer.
    Rivera E; Mejia JA; Arun BK; Adinin RB; Walters RS; Brewster A; Broglio KR; Yin G; Esmaeli B; Hortobagyi GN; Valero V
    Cancer; 2008 Apr; 112(7):1455-61. PubMed ID: 18300256
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
    Califano R; Griffiths R; Lorigan P; Ashcroft L; Taylor P; Burt P; Lee L; Chittalia A; Harris M; Faivre-Finn C; Thatcher N; Blackhall F
    Lung Cancer; 2011 Sep; 73(3):338-44. PubMed ID: 21296449
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer.
    Ford HE; Yap YS; Miles DW; Makris A; Hall M; Miller L; Harries M; Smith IE; Johnston SR
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):809-15. PubMed ID: 16528527
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Weekly docetaxel in metastatic breast cancer patients: no superior benefits compared to three-weekly docetaxel.
    Schröder CP; de Munck L; Westermann AM; Smit WM; Creemers GJ; de Graaf H; Stouthard JM; van Deijk G; Erjavec Z; van Bochove A; Vader W; Willemse PH
    Eur J Cancer; 2011 Jun; 47(9):1355-62. PubMed ID: 21251813
    [TBL] [Abstract][Full Text] [Related]  

  • 71.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 72.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 73.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.